Lyubov A. Kisakova

Lyubov A. Kisakova


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LKLyubov A. Kisakova
Lyubov A. Kisakova
Evgeny ApartsinEvgeny Apartsin
Evgeny Apartsin
LNLily F. Nizolenko
Lily F. Nizolenko
LKLarisa I. Karpenko
Larisa I. Karpenko
DNA and RNA vaccines (nucleic acid-based vaccines) are a promising platform for vaccine development. The first mRNA vaccines (Moderna and Pfizer/BioNTech) were approved in 2020, and a DNA vaccine (Zydus Cadila, India), in 2021. They display unique benefits in the current COVID-19 pandemic. Nucleic acid-based vaccines have a number of advantages, such as safety, efficacy, and low cost. They are potentially faster to develop, cheaper to produce, and easier to store and transport. A crucial step in the technology of DNA or RNA vaccines is choosing an efficient delivery method. Nucleic acid delivery using liposomes is the most popular approach today, but this method has certain disadvantages. Therefore, studies are actively underway to develop various alternative delivery methods, among which synthetic cationic polymers such as dendrimers are very attractive. Dendrimers are three-dimensional nanostructures with a high degree of molecular homogeneity, adjustable size, multivalence, high surface functionality, and high aqueous solubility. The biosafety of some dendrimers has been evaluated in several clinical trials presented in this review. Due to these important and attractive properties, dendrimers are already being used to deliver a number of drugs and are being explored as promising carriers for nucleic acid-based vaccines. This review summarizes the literature data on the development of dendrimer-based delivery systems for DNA and mRNA vaccines.

13 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
DKDenis Nicolaevich Kisakov
Denis Nicolaevich Kisakov
LKLarisa I. Karpenko
Larisa I. Karpenko
LKLyubov A. Kisakova
Lyubov A. Kisakova
SSSergei V. Sharabrin
Sergei V. Sharabrin
MBMariya Borgoyakova
Mariya Borgoyakova
AIAlexander Ilyichev
Alexander Ilyichev
Background: Although mRNA vaccines encapsulated in lipid nanoparticles (LNPs) have demonstrated a safety profile with minimal serious adverse events in clinical trials, there is opportunity to further reduce mRNA reactogenicity. The development of naked mRNA vaccines could improve vaccine tolerability. Naked nucleic acid delivery using the jet injection method may be a solution. Methods: In the first part of the study, the optimal conditions providing low traumatization and high expression of the model mRNA-GFP molecule in the tissues of laboratory animals were determined. Then, we used the selected protocol to immunize BALB/c mice with mRNA-RBD encoding the SARS-CoV-2 receptor-binding domain (RBD). It was demonstrated that mice vaccinated with naked mRNA-RBD developed a high level of specific antibodies with virus-neutralizing activity. The vaccine also induced a strong RBD-specific T-cell response and reduced the viral load in the lungs of the animals after infection with the SARS-CoV-2 virus. The level of immune response in mice immunized with mRNA-RBD using a spring-loaded jet injector was comparable to that in animals immunized with mRNA-RBD encapsulated in LNPs. Results: In this study, the efficacy of an inexpensive, simple, and safe method of mRNA delivery using a spring-loaded jet injector was evaluated and validated. Conclusions: Our findings suggest that the jet injection method may be a possible alternative to LNPs for delivering mRNA vaccines against SARS-CoV-2 infection.

1 February 2026 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
LKLyubov A. Kisakova
Lyubov A. Kisakova
SIS. A. Ilyicheva
S. A. Ilyicheva
ARA. P. Rudometov
A. P. Rudometov

1 January 2025 in Bulletin of Experimental Biology and Medicine
Verified
Journal Article
Closed access
LKLyubov A. Kisakova
Lyubov A. Kisakova
SIS.A. Ilyicheva
S.A. Ilyicheva
ARA.P. Rudometov
A.P. Rudometov